Clinical phase I study of meropenem

CHEMOTHERAPY

Volumn 40, Issue , 1992, Pages 258-275

  Nakashima, Mitsuyoshi ^a   Uematsu, Toshihiko ^a   Kanamaru, Mitsutaka ^a   Ueno, Kazue ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b GIFU UNIVERSITY   (Japan)

Author keywords

Meropenem

Indexed keywords

CARBAPENEM; MEROPENEM;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG SAFETY; FECES MICROFLORA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL;

EID: 0026625405     PISSN: 00093165     EISSN: None     Source Type: Journal    
DOI: 10.11250/chemotherapy1953.40.Supplement1_258     Document Type: Article

References (17)

1. Tanio T, Nouda H, Tada E, Kohzuki T, Kato M, Fukasawa M, Okuda T, Kamidono S: carhapenem antibiotic: renal dehydropeptidase-I stability and pharmacokinetics in animals. 27th ICAAC, New York. Abstract no. 758, 229, 1987.
2. Sumita Y, Inoue M, Mitsuhashi S: In vitro antibacterial activity and β-lactamase stability of the new carbapenem SM-7338, Eur J Microbio Infect Dis 8: 908–916.1989
3. Goto S. Miyazaki S. Kaneko Y: The in vitro activity of SM-7: 7338 and assessment of its clinical usefulness 29th ICAAC, Houston. Abstract no 227. 138. 38, 1989
4. Harrison M. P., Moss S. R., Featherstone A., Fowkes A. G. Sanders A. M.: The disposition and metabolism of meropenem in laboratory annuals and man J Antimicrob Chemother 24 Suppl. A 265–277, 1989
5. Meropenem Chemotherapy 40 (S-1): 182–191. 1992
6. Russel A W, Topham J C: Meropenem Chemotherapy 40 (S-1): 192–206, 1992
7. Berent C D, Topham J C: Meropenem Chemotherapy 40 (S-1): 207–221, 1992
8. Russel A W, Freeman S J, Siddall E A: Meropenem Chemotherapy 40 (S-1): 238–250. 1992
9. Edwards J R, Grindey A J: Meropenem Chemotherapy 10 (S-1): 163–174. 1992
10. 32 MK-0787/MK-0791, 1984
11. Topham J, Murgatroyd L B, Jones D V, Goonetilleke V R, Wright J: Safety evaluation of meropenem in animals: studies on the kidney. J. Antimicrob. Chemother. 23 Suppl. A: 287–306, 1989
12. Sunagawa M, Matsumura H, Ohno Y, Nakamura M, Fukasawa M: Meropenem, a novel 1 β-methyl carbapenem with low neurotoxic side-effects: structure-activity relationship for convulsive liability. 31st ICAAC, Chicago. Abstract no. 167, 1991
13. Bastain W, Bax R P, Featherstone A, Wilkinson D: The pharmacokinetics in volunteers of SM-7338 a new, broad spectrum, DHP-stable, carbapenem 28th ICAAC, Los Angeles. Abstract no. 607, 215, 1988
14. 3 p. 94–103, 1982
15. Meropenem Chemotherapy 40 (S-1): 114–122, 1992
16. Yamaoka K, Tanigawara Y, Nakagawa T: A pharmacokinetic analysis program (MULTI) for microcomputer, J. Phrm. Dyn., 4: 879–885, 1981
17. 38 CS-976, 1990